CKD progression is measurable, predictable, and — in many cases — modifiable. But only if you are actually tracking it systematically across your panel. Most nephrologists manage hundreds of CKD patients at various stages, plus dialysis patients, plus transplant recipients. Without population-level eGFR and UACR trending, patients slip through the cracks between stages.
Glance provides CKD staging analytics, lab trending with renal-specific reference ranges, BP control tracking, medication adherence monitoring, and HCC coding for the full spectrum of renal disease.
Schedule a Demo See FeaturesCKD management is a longitudinal game. Glance gives you the tools to track disease progression, intervene early, and capture the coding that reflects your patients' true acuity.
Automated CKD staging based on eGFR and UACR values. Trending over 6, 12, and 24 months to identify patients with declining kidney function. Alerts when patients approach stage transitions (e.g., IIIb to IV) that trigger new management milestones like dialysis access planning or transplant referral.
Lab interpretation with CKD-appropriate reference ranges. Potassium, phosphorus, calcium, PTH, hemoglobin, and bicarbonate all interpreted in the context of CKD stage. Trending that shows trajectory, not just a single point. Flag abnormalities that require intervention before they become emergencies.
Hypertension control is the single most modifiable factor in CKD progression. Track BP control rates across your renal panel with a target of <130/80 for CKD patients. Monitor PDC for ACEi/ARBs, calcium channel blockers, and diuretics. Identify patients with uncontrolled BP who are also non-adherent.
Capture CKD by stage (HCC 138-141), ESRD/dialysis status (HCC 134-137), transplant status, and secondary diagnoses like renal osteodystrophy and anemia of CKD. Accurate staging codes directly affect RAF scores, and many nephrology practices undercode CKD severity based on the most recent eGFR.
Dialysis patients are among the most expensive in any population. Track the cost trajectory as patients approach ESRD, model the financial impact of delaying dialysis initiation by 6 months through aggressive CKD management, and benchmark dialysis costs against VBC targets.